These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28275117)

  • 1. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
    García-Carbonero R; van Cutsem E; Rivera F; Jassem J; Gore I; Tebbutt N; Braiteh F; Argiles G; Wainberg ZA; Funke R; Anderson M; McCall B; Stroh M; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Hurwitz H
    Oncologist; 2017 Apr; 22(4):375-e30. PubMed ID: 28275117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
    Bendell JC; Hochster H; Hart LL; Firdaus I; Mace JR; McFarlane JJ; Kozloff M; Catenacci D; Hsu JJ; Hack SP; Shames DS; Phan SC; Koeppen H; Cohn AL
    Oncologist; 2017 Mar; 22(3):264-271. PubMed ID: 28209746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J
    J Clin Oncol; 2008 Apr; 26(12):2013-9. PubMed ID: 18421054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Tian Y; Xu F; Sidhu R
    Ann Oncol; 2014 Jul; 25(7):1346-1355. PubMed ID: 24718886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
    Elez E; Hendlisz A; Delaunoit T; Sastre J; Cervantes A; Varea R; Chao G; Wallin J; Tabernero J
    Br J Cancer; 2016 Feb; 114(4):372-80. PubMed ID: 26766738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
    Meropol NJ; Feng Y; Grem JL; Mulcahy MF; Catalano PJ; Kauh JS; Hall MJ; Saltzman JN; George TJ; Zangmeister J; Chiorean EG; Cheema PS; O'Dwyer PJ; Benson AB
    Cancer; 2018 Feb; 124(4):688-697. PubMed ID: 29211295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.
    Seufferlein T; Lausser L; Stein A; Arnold D; Prager G; Kasper-Virchow S; Niedermeier M; Müller L; Kubicka S; König A; Büchner-Steudel P; Wille K; Berger AW; Kestler AMR; Kraus JM; Werle SD; Perkhofer L; Ettrich TJ; Kestler HA
    PLoS One; 2024; 19(6):e0304324. PubMed ID: 38875244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
    Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.
    Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J
    J Clin Oncol; 2023 Jul; 41(21):3663-3669. PubMed ID: 37459755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
    Han SW; Oh DY; Im SA; Park SR; Lee KW; Song HS; Lee NS; Lee KH; Choi IS; Lee MH; Kim MA; Kim WH; Bang YJ; Kim TY
    Cancer Sci; 2010 Mar; 101(3):793-9. PubMed ID: 20047592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.
    Wang F; Jin Y; Wang M; Luo HY; Fang WJ; Wang YN; Chen YX; Huang RJ; Guan WL; Li JB; Li YH; Wang FH; Hu XH; Zhang YQ; Qiu MZ; Liu LL; Wang ZX; Ren C; Wang DS; Zhang DS; Wang ZQ; Liao WT; Tian L; Zhao Q; Xu RH
    Nat Med; 2024 Apr; 30(4):1035-1043. PubMed ID: 38438735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study.
    Han G; Cui L; Sun C; Yu L; Liu S
    Front Oncol; 2023; 13():1259713. PubMed ID: 38125935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
    Legoux JL; Faroux R; Barrière N; Le Malicot K; Tougeron D; Lorgis V; Guerin-Meyer V; Bourgeois V; Malka D; Aparicio T; Baconnier M; Lebrun-Ly V; Egreteau J; Khemissa Akouz F; Terme M; Lepage C; Boige V
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
    Segal NH; Tie J; Kopetz S; Ducreux M; Chen E; Dienstmann R; Hollebecque A; Reilley MJ; Elez E; Cosaert J; Cain J; Soo-Hoo Y; Hewson N; Cooper ZA; Kumar R; Tabernero J
    Br J Cancer; 2024 Oct; 131(6):1005-1013. PubMed ID: 39048638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
    García-Carbonero R; van Cutsem E; Rivera F; Jassem J; Gore I; Tebbutt N; Braiteh F; Argiles G; Wainberg ZA; Funke R; Anderson M; McCall B; Stroh M; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Hurwitz H
    Oncologist; 2017 Oct; 22(10):1281. PubMed ID: 29018169
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
    Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
    Nagata N; Mishima H; Kurosawa S; Oba K; Sakamoto J
    Clin Colorectal Cancer; 2017 Jun; 16(2):154-157.e1. PubMed ID: 28284575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
    Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
    Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
    Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.